



## **AVITA Medical to Present at TD Cowen 44th Annual Health Care Conference**

February 29, 2024

VALENCIA, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that David O'Toole, Chief Financial Officer, will present at TD Cowen's 44<sup>th</sup> Annual Health Care Conference on Tuesday, March 5, 2024, at 9:50 a.m. Eastern Time.

A live audio webcast of the presentation will be available under the Events & Presentations section of AVITA Medical's website at <https://ir.avitamedical.com>. A replay of the webcast will be available at the same location for approximately 90 days following the conclusion of the event.

### **About AVITA Medical, Inc.**

AVITA Medical<sup>®</sup> is a commercial-stage regenerative medicine company transforming the standard of care in wound care management and skin restoration with innovative devices. At the forefront of our platform is the RECELL<sup>®</sup> System, approved by the Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient's own skin to create Spray-On Skin<sup>™</sup> Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm<sup>®</sup>, a biosynthetic wound matrix, in the United States.

In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System is TGA-registered in Australia, received CE-mark approval in Europe and has PMDA approval in Japan.

To learn more, visit [www.avitamedical.com](http://www.avitamedical.com).

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.

Investor & Media Contact: Jessica Ekeberg Phone +1-661-904-9269 [investor@avitamedical.com](mailto:investor@avitamedical.com) [media@avitamedical.com](mailto:media@avitamedical.com)